TransMedics Group (NASDAQ:TMDX) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, August 7th. Analysts expect TransMedics Group to post earnings of ($0.41) per share for the quarter.
TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Wednesday, June 12th. The company reported ($4.86) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.81) by ($4.05). The business had revenue of $4.68 million during the quarter, compared to analyst estimates of $4.43 million. On average, analysts expect TransMedics Group to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
NASDAQ TMDX opened at $21.89 on Tuesday. The company’s 50-day moving average is $26.10. TransMedics Group has a fifty-two week low of $19.76 and a fifty-two week high of $31.54.
A number of equities research analysts have recently commented on TMDX shares. JPMorgan Chase & Co. started coverage on TransMedics Group in a research report on Tuesday, May 28th. They set an “overweight” rating and a $34.00 target price on the stock. Canaccord Genuity started coverage on TransMedics Group in a research report on Tuesday, May 28th. They set a “buy” rating and a $37.00 target price on the stock. Morgan Stanley started coverage on TransMedics Group in a research report on Tuesday, May 28th. They set an “equal weight” rating on the stock. Zacks Investment Research cut TransMedics Group from a “hold” rating to a “sell” rating in a research report on Thursday, August 1st. Finally, Cowen started coverage on TransMedics Group in a research report on Tuesday, May 28th. They set an “outperform” rating and a $40.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $37.00.
About TransMedics Group
TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.